ALBIZIA JULIBRISSIN: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews

Overview

Albizia julibrissin is a tree that was originally grown in southern and eastern Asia. The flowers and stem bark are used to make medicine.

Albizia julibrissin is used for anxiety, cancer, insomnia, skin infections, and other conditions, but there is no good scientific evidence to support its use.

How does it work ?

The chemicals in Albizia julibrissin might have calming, sleep inducing, anticancer, and antioxidant effects.

Uses & Effectiveness

Insufficient Evidence for

Anxiety.
Cancer.
Depression.
Insomnia.
Sore throat.
To improve mood.
Trauma.
Insect bites.
Skin infection (boils and abscesses).
Bed sores (pressure ulcers).
Fractures.
Sprains.
Other conditions.

More evidence is needed to rate Albizia julibrissin for these uses.

Side Effects

When taken by mouth: There isn't enough reliable information to know if Albizia julibrissin is safe or what the side effects might be.

When applied to the skin: There isn't enough reliable information to know if Albizia julibrissin is safe or what the side effects might be.

Special Precautions and Warnings

Pregnancy and breast-feeding: There isn't enough reliable information to know if Albizia julibrissin is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use.

Surgery: Albizia julibrissin might affect the central nervous system. It might increase the effects of anesthesia and other medications on the brain during and after surgery. Stop taking Albizia julibrissin at least 2 weeks before a scheduled surgery.

Interactions

Moderate Interaction

Be cautious with this combination

Sedative medications (CNS depressants) interacts with ALBIZIA JULIBRISSIN
Albizia julibrissin might cause sleepiness and drowsiness. Medications that cause sleepiness are called sedatives. Taking Albizia julibrissin along with sedative medications might cause too much sleepiness.

Some sedative medications include pentobarbital (Nembutal), phenobarbital (Luminal), secobarbital (Seconal), clonazepam (Klonopin), lorazepam (Ativan), zolpidem (Ambien), and others.

Dosing

The appropriate dose of Albizia julibrissin depends on several factors such as the user's age, health, and several other conditions. At this time there is not enough scientific information to determine an appropriate range of doses for Albizia julibrissin. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult your pharmacist or physician or other healthcare professional before using.

View References

REFERENCES:

Ikeda, T., Fujiwara, S., Araki, K., Kinjo, J., Nohara, T., and Miyoshi, T. Cytotoxic glycosides from Albizia julibrissin. J Nat Prod 1997;60(2):102-107. View abstract.

Jung, M. J., Chung, H. Y., Kang, S. S., Choi, J. H., Bae, K. S., and Choi, J. S. Antioxidant activity from the stem bark of Albizzia julibrissin. Arch Pharm Res 2003;26(6):458-462. View abstract.

Jung, M. J., Kang, S. S., and Choi, J. S. A new (E)4-hydroxy-dodec-2-enedioic acid from the stem bark of Albizzia julibrissin. Arch Pharm Res 2003;26(3):207-209. View abstract.

Jung, M. J., Kang, S. S., Jung, H. A., Kim, G. J., and Choi, J. S. Isolation of flavonoids and a cerebroside from the stem bark of Albizzia julibrissin. Arch Pharm Res 2004;27(6):593-599. View abstract.

Jung, M. J., Kang, S. S., Jung, Y. J., and Choi, J. S. Phenolic glycosides from the stem bark of Albizzia julibrissin. Chem Pharm Bull (Tokyo) 2004;52(12):1501-1503. View abstract.

Kang, T. H., Jeong, S. J., Kim, N. Y., Higuchi, R., and Kim, Y. C. Sedative activity of two flavonol glycosides isolated from the flowers of Albizzia julibrissin Durazz. J Ethnopharmacol 2000;71(1-2):321-323. View abstract.

Li, Z. P., Gao, S., Hao, C. S., and Fan, G. M. [Studies on chemical constituents from the flower of Albizzia julibrissin Durazz]. Zhongguo Zhong Yao Za Zhi 2000;25(2):103-104. View abstract.

Liang, H., Tong, W. Y., Zhao, Y. Y., Cui, J. R., and Tu, G. Z. An antitumor compound julibroside J28 from Albizia julibrissin. Bioorg Med Chem Lett 2005;15(20):4493-4495. View abstract.

Roy, B., Pramanik, K., and Mukhopadhyay, B. Synthesis of a tetra- and a trisaccharide related to an anti-tumor saponin "Julibroside J28" from Albizia julibrissin. Glycoconj J 2008;25(2):157-166. View abstract.

Won, H. J., Han, C. H., Kim, Y. H., Kwon, H. J., Kim, B. W., Choi, J. S., and Kim, K. H. Induction of apoptosis in human acute leukemia Jurkat T cells by Albizzia julibrissin extract is mediated via mitochondria-dependent caspase-3 activation. J Ethnopharmacol 2006;106(3):383-389. View abstract.

Woo WS, Kang SS. Isolation of a new monoterpene conjugated triterpenoid from the stem bark of Albizzia julibrissin. J Nat Prod 1984;47(3):547-9. View abstract.

Xu, T. H., Li, H. T., Xu, Y. J., Zhao, H. F., Xie, S. X., Han, D., Si, Y. S., Li, Y., Niu, J. Z., and Xu, D. M. A new triterpenoid saponin from Albizia julibrissin Durazz. J Asian Nat Prod Res 2008;10(7-8):781-785. View abstract.

Zheng, L., Zheng, J., Wu, L. J., and Zhao, Y. Y. Julibroside J8-induced HeLa cell apoptosis through caspase pathway. J Asian Nat Prod Res 2006;8(5):457-465. View abstract.

Zou, K., Cui, J. R., Wang, B., Zhao, Y. Y., and Zhang, R. Y. A pair of isomeric saponins with cytotoxicity from Albizzia julibrissin. J Asian Nat Prod Res 2005;7(6):783-789. View abstract.

Zou, K., Tong, W. Y., Liang, H., Cui, J. R., Tu, G. Z., Zhao, Y. Y., and Zhang, R. Y. Diastereoisomeric saponins from Albizia julibrissin. Carbohydr Res 2005;340(7):1329-1334. View abstract.

Zou, K., Zhao, Y. Y., and Zhang, R. Y. A cytotoxic saponin from Albizia julibrissin. Chem Pharm Bull (Tokyo) 2006;54(8):1211-1212. View abstract.

Strasser, F., Luftner, D., Possinger, K., Ernst, G., Ruhstaller, T., Meissner, W., Ko, Y. D., Schnelle, M., Reif, M., and Cerny, T. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol. 7-20-2006;24(21):3394-3400. View abstract.

Tomida, I., Azuara-Blanco, A., House, H., Flint, M., Pertwee, R. G., and Robson, P. J. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma. 2006;15(5):349-353. View abstract.

Trembly B, Sherman M. Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Marijuana '90 International Conference on Cannabis and Cannabinoids 1990;2:5.

Wade, D. T., Collin, C., Stott, C., and Duncombe, P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult.Scler. 2010;16(6):707-714. View abstract.

Wade, D. T., Makela, P., Robson, P., House, H., and Bateman, C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult.Scler. 2004;10(4):434-441. View abstract.

Wade, D. T., Robson, P., House, H., Makela, P., and Aram, J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin.Rehabil. 2003;17(1):21-29. View abstract.

Watzl, B., Scuderi, P., and Watson, R. R. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. Int J Immunopharmacol. 1991;13(8):1091-1097. View abstract.

Weiss, L., Zeira, M., Reich, S., Har-Noy, M., Mechoulam, R., Slavin, S., and Gallily, R. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 2006;39(2):143-151. View abstract.

Zuardi, A. W., Shirakawa, I., Finkelfarb, E., and Karniol, I. G. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 1982;76(3):245-250. View abstract.

"GW Pharmaceuticals plc and Its U.S. Subsidiary Greenwich Biosciences, Inc. Announce That EPIDIOLEX® (cannabidiol) Oral Solution Has Been Descheduled And Is No Longer A Controlled Substance." GW Pharmaceuticals, 6 April 2020. https://ir.gwpharm.com/node/11356/pdf. Press release.

97021 Jadoon KA, Ratcliffe SH, Barrett DA, et al. Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care. 2016 Oct;39(10):1777-86. View abstract.

Abuhasira R, Haviv YS, Leiba M, Leiba A, Ryvo L, Novack V. Cannabis is associated with blood pressure reduction in older adults - A 24-hours ambulatory blood pressure monitoring study. Eur J Intern Med. 2021:S0953-6205(21)00005-4. View abstract.

Afshar S, Khalili S, Amin G, Abbasinazari M. A Phase I Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety Profile of a Sublingually Administered Cannabidiol /Delta 9-tetrahydrocannabidiol (10: 1) Regimen in Diabetes Type 2 Patients. Iran J Pharm Res 2023;21(1):e132647. View abstract.

Agriculture Improvement Act, S. 10113, 115th Cong. (2018) or S. 12619, 115th Cong. (2018).

Alaia MJ, Hurley ET, Vasavada K, et al. Buccally absorbed cannabidiol shows significantly superior pain control and improved satisfaction immediately after arthroscopic rotator cuff repair: A placebo-controlled, double-blinded, randomized trial. Am J Sports Med 2022;50(11):3056-3063. View abstract.

de Almeida CMO, Brito MMC, Bosaipo NB, et al. Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder. Mov Disord. 2021. View abstract.

de Carvalho Reis R, Almeida KJ, da Silva Lopes L, de Melo Mendes CM, Bor-Seng-Shu E. Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis. Epilepsy Behav. 2020;102:106635. View abstract.

de Faria SM, de Morais Fabrício D, Tumas V, et al. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease. J Psychopharmacol. 2020 Jan 7:269881119895536. View abstract.

De Filippis D, Esposito G, Cirillo C, et al. Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PLoS One 2011;6(12):e28159. View abstract.

Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014;55(6):791-802. View abstract.

Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet Syndrome. N Engl J Med. 2017 May 25;376(21):2011-2020. View abstract.

Devinsky O, Kraft K, Rusch L, Fein M, Leone-Bay A. Improved Bioavailability with Dry Powder Cannabidiol Inhalation: A Phase 1 Clinical Study. J Pharm Sci 2021. View abstract.